Can-Fite BioPharma Ltd. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
CANF NYSE American 2830 www.canfite.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Can-Fite BioPharma Ltd.

Can-Fite Announces Eurasian Patent Allowance Supporting Piclidenoson Development and Commercialization in Lowe Syndrome - Nov 2nd, 2026 5:00 am
Can-Fite Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026 - Oct 26th, 2026 5:00 am
Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation - Sep 9th, 2026 5:00 am
Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study - Sep 8th, 2026 6:20 am
Can-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer Study - Sep 2nd, 2026 9:48 am
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds - Sep 2nd, 2026 7:02 am
Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study - Sep 2nd, 2026 5:00 am
Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer - Aug 17th, 2026 5:00 am
Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates - Aug 12th, 2026 5:00 am
Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome - Aug 3rd, 2026 5:00 am
Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology - Jul 20th, 2026 5:00 am
Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer - Jul 14th, 2026 5:00 am
Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027 - Jul 6th, 2026 5:00 am
Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease - Jul 1st, 2026 5:00 am
Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology - Jun 26th, 2026 5:00 am
Can-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson - Jun 22nd, 2026 5:00 am
Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026 - Jun 17th, 2026 5:00 am
Can-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson’s RAS Signaling Inhibition Mechanism - Jun 2nd, 2026 5:00 am
Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market - May 18th, 2026 5:00 am